|By Marketwired .||
|July 7, 2014 04:00 PM EDT||
TUSTIN, CA -- (Marketwired) -- 07/07/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2014 ended April 30, 2014 on July 14, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the fourth quarter ended April 30, 2014 of FY 2014 and will review recent progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through July 21, 2014 by calling (855) 859-2056, or (404) 537-3406 and using passcode 66161283.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has a wholly-owned in-house cGMP contract manufacturing subsidiary, Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Jul. 25, 2016 01:15 PM EDT Reads: 1,895
Jul. 25, 2016 01:00 PM EDT Reads: 1,921
Jul. 25, 2016 12:15 PM EDT Reads: 403
Jul. 25, 2016 12:00 PM EDT Reads: 1,663
Jul. 25, 2016 12:00 PM EDT Reads: 1,812
Jul. 25, 2016 11:45 AM EDT Reads: 861
Jul. 25, 2016 11:00 AM EDT Reads: 1,573
Jul. 25, 2016 11:00 AM EDT Reads: 897
Jul. 25, 2016 10:53 AM EDT Reads: 317
Jul. 25, 2016 10:30 AM EDT Reads: 290
Jul. 25, 2016 10:30 AM EDT Reads: 1,937
Jul. 25, 2016 10:15 AM EDT Reads: 1,864
Jul. 25, 2016 10:00 AM EDT Reads: 983
Jul. 25, 2016 09:45 AM EDT Reads: 1,128
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 25, 2016 09:45 AM EDT Reads: 1,668